Angel Medical Systems (AngelMed) accomplished several major milestones in 2021 and the company is prepared to leverage those accomplishments to expand the commercialization of its Guardian implantable cardiac monitor in 2022.
In June, the US Food and Drug Administration (FDA) approved AngelMed’s second-generation version of The Guardian implantable cardiac detection monitor and patient-warning system for acute coronary syndrome (ACS) events, including silent heart attacks
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?